{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-035812","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2024-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.913817+00:00","generated_at":"2026-05-29T21:48:57.480715+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Genprex enters exclusive license with Univ of Michigan for Reqorsa in ALK+ lung cancer","bullets":["License grants Genprex worldwide exclusive rights to University of Michigan patents for Reqorsa gene therapy combined with ALK-inhibitors for ALK-EML4 positive NSCLC.","Preclinical data at AACR April 2024 showed Reqorsa induced apoptosis in alectinib-resistant EML4-ALK positive NSCLC cell lines.","Researchers believe results support further clinical study of Reqorsa as an anti-ALK NSCLC treatment strategy."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-035812","json":"https://secwatch.observer/filing/0001437749-24-035812.json","markdown":"https://secwatch.observer/filing/0001437749-24-035812.md","text":"https://secwatch.observer/filing/0001437749-24-035812.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924035812/0001437749-24-035812-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924035812/gnpx20241119_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T21:48:57.480715+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}